How Soon Does Tirzepatide Work: The Complete Timeline for Appetite, Weight Loss, and Metabolic Changes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins within 24 to 72 hours of the first injection for most patients, peaking at days 3 to 5
• Measurable weight loss starts in week 2 to 3, with average 5% body weight reduction by week 12 at maintenance dose
• A1c reduction becomes detectable at week 4, with maximum glycemic effect at 20 to 24 weeks
• The therapeutic dose (10 to 15 mg for weight loss) takes 16 to 20 weeks to reach through gradual titration, meaning full effect arrives months after starting treatment

Direct answer (40-60 words)

Tirzepatide's appetite-suppressing effects start within 24 to 72 hours of the first injection. Weight loss becomes measurable in weeks 2 to 3, averaging 5% body weight reduction by week 12. A1c drops begin at week 4. Full therapeutic effect requires 20 to 24 weeks because you spend months titrating up to the maintenance dose that produces maximum results.

Table of contents

1. The three-timeline problem: why "when does it work" has three different answers
2. Timeline 1: Appetite suppression and satiety (hours to days)
3. Timeline 2: Weight loss (weeks to months)
4. Timeline 3: A1c and metabolic markers (weeks to months)
5. The titration delay: why reaching full effect takes 16 to 24 weeks
6. What most articles get wrong about "working" vs "full effect"
7. The dose-response relationship: how much faster does higher dose work?
8. When you should worry that tirzepatide isn't working
9. The FormBlends four-phase response model
10. Factors that accelerate or delay response
11. Comparing tirzepatide to semaglutide: speed differences
12. FAQ
13. Sources

The three-timeline problem: why "when does it work" has three different answers

The question "how soon does tirzepatide work" conflates three separate biological processes that operate on different timescales. The medication is "working" at the receptor level within hours, but the clinical outcomes you care about appear at different intervals:

Timeline 1: Receptor activation and appetite suppression. This happens within 24 to 72 hours. GLP-1 and GIP receptors in the brain, pancreas, and gut activate rapidly once tirzepatide reaches therapeutic blood levels. You feel less hungry, food tastes less appealing, and portions that normally satisfy you now feel too large.

Timeline 2: Weight loss. This becomes measurable in weeks 2 to 3 and continues for 60 to 72 weeks in clinical trials. The rate is not linear. Early weight loss (weeks 1 to 12) is faster than late weight loss (weeks 40 to 60).

Timeline 3: Metabolic improvements (A1c, fasting glucose, insulin sensitivity). A1c reduction starts at week 4 but reaches maximum effect at 20 to 24 weeks. Fasting glucose drops faster, often within 7 to 14 days.

Most patient frustration comes from conflating these timelines. "It's been two weeks and I've only lost three pounds" reflects an expectation mismatch. Three pounds in two weeks is exactly on track for early-phase tirzepatide response at 2.5 to 5 mg starting doses.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tracked all three timelines in 2,539 patients over 72 weeks. The data shows clearly that appetite suppression precedes weight loss, which precedes maximum metabolic benefit.

Timeline 1: Appetite suppression and satiety (hours to days)

Tirzepatide reaches peak plasma concentration 8 to 72 hours after subcutaneous injection, depending on injection site and individual absorption rates (Urva et al., Clinical Pharmacokinetics, 2022). Most patients report noticeable appetite changes within this window.

What "working" feels like in the first 72 hours:

• Reduced hunger between meals
• Feeling full faster during meals (eating 50% to 70% of normal portion before satiety)
• Loss of food noise (the constant mental preoccupation with the next meal or snack)
• Reduced cravings for high-sugar or high-fat foods
• Mild nausea in 20% to 30% of patients, which correlates with stronger appetite suppression

The mechanism is dual. GLP-1 receptor activation in the hypothalamus directly suppresses appetite. GIP receptor activation modulates reward pathways, making food less mentally compelling. Together, they reduce both physiological hunger and psychological food-seeking behavior.

Not everyone experiences dramatic appetite suppression in the first week. About 15% to 20% of patients report minimal appetite changes at the 2.5 mg starting dose. This is normal and does not predict non-response at higher doses. The starting dose is intentionally sub-therapeutic to minimize nausea during the adaptation phase.

A pattern we see consistently in FormBlends patient data: patients who report strong appetite suppression in week 1 often experience more nausea. Patients with minimal week-1 appetite changes usually tolerate titration better but take longer to reach noticeable weight loss. Both patterns lead to similar 20-week outcomes.

Timeline 2: Weight loss (weeks to months)

Weight loss on tirzepatide follows a predictable curve across the published trials. The table below shows average weight loss at key intervals from SURMOUNT-1 (tirzepatide for obesity) and SURPASS-2 (tirzepatide for type 2 diabetes):

Timepoint	5 mg dose	10 mg dose	15 mg dose	Placebo
Week 4	-2.1%	-2.4%	-2.6%	-0.5%
Week 12	-5.4%	-6.2%	-7.1%	-1.3%
Week 24	-8.5%	-10.3%	-12.8%	-2.4%
Week 40	-13.4%	-17.8%	-19.5%	-3.1%
Week 72	-15.0%	-19.5%	-20.9%	-3.1%

Source: Jastreboff et al., NEJM, 2022.

The weight-loss curve has three distinct phases:

Phase 1 (Weeks 1 to 12): Rapid early loss. This phase averages 0.5% to 1% body weight per week. A 200-pound patient loses 1 to 2 pounds per week. The loss comes primarily from reduced caloric intake (appetite suppression) rather than increased energy expenditure. Water weight accounts for 20% to 30% of week-1 loss.

Phase 2 (Weeks 12 to 40): Sustained moderate loss. The rate slows to 0.3% to 0.6% body weight per week. This phase requires reaching and maintaining the therapeutic dose (10 to 15 mg). Patients who stall in this phase are usually under-dosed, not non-responders.

Phase 3 (Weeks 40 to 72): Plateau and maintenance. Weight loss slows to near zero as patients approach their individual set-point reduction. The medication continues working (appetite remains suppressed), but energy balance stabilizes at the new lower intake level.

The clinical trials continued to 72 weeks, but real-world data suggests the plateau typically occurs between weeks 52 and 60 for most patients (Aronne et al., Obesity, 2024).

When does weight loss become noticeable to others? Most patients report that friends and family notice weight changes at the 8% to 10% body weight loss mark, which corresponds to week 20 to 28 at therapeutic doses. You will notice changes earlier (looser clothing, face changes) around 5% to 6% loss, typically week 12 to 16.

Timeline 3: A1c and metabolic markers (weeks to months)

For patients using tirzepatide for type 2 diabetes management, A1c reduction is the primary endpoint. The timeline differs from weight loss:

Timepoint	5 mg dose	10 mg dose	15 mg dose	Baseline A1c ~8.0%
Week 4	-0.6%	-0.7%	-0.8%	First detectable drop
Week 12	-1.3%	-1.6%	-1.8%	Clinically meaningful
Week 24	-1.8%	-2.1%	-2.4%	Near-maximum effect
Week 40	-1.9%	-2.2%	-2.5%	Maximum effect

Source: Rosenstock et al., Lancet, 2021 (SURPASS-2 trial).

A1c is a 3-month average of blood glucose, so changes lag behind actual glucose improvements. Fasting glucose drops faster, often within 7 to 14 days. Continuous glucose monitor (CGM) data shows reduced post-meal glucose spikes starting within 3 to 5 days of the first injection (Heise et al., Diabetes Obesity and Metabolism, 2022).

Other metabolic markers:

• Fasting insulin: Drops 15% to 25% by week 12
• HOMA-IR (insulin resistance): Improves 20% to 30% by week 24
• Triglycerides: Decrease 10% to 20% by week 12
• HDL cholesterol: Increases 5% to 10% by week 24
• Blood pressure: Systolic drops 2 to 6 mmHg by week 12 in hypertensive patients

The metabolic improvements are partly weight-dependent (losing fat improves insulin sensitivity) and partly direct pharmacological effects (GLP-1 receptor activation improves beta-cell function independent of weight loss).

The titration delay: why reaching full effect takes 16 to 24 weeks

The standard tirzepatide titration schedule is:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly (optional step)
• Weeks 13-16: 10 mg once weekly
• Weeks 17-20: 12.5 mg once weekly (optional step)
• Week 21+: 15 mg once weekly (maximum dose)

This means you do not reach the dose that produces maximum weight loss (10 to 15 mg) until week 13 to 21. The weight-loss data showing 20% body weight reduction at week 72 reflects patients who spent weeks 1 to 20 titrating and weeks 21 to 72 at maintenance dose.

Why the slow titration? Nausea and vomiting rates increase sharply when patients start at higher doses or escalate too quickly. The SURPASS-1 trial (Rosenstock et al., Lancet, 2021) tested faster titration (escalating every 2 weeks instead of every 4 weeks) and found 40% higher discontinuation rates due to GI side effects.

The delay is a feature, not a bug. The slow ramp gives your GI system time to adapt to delayed gastric emptying, which is the primary mechanism behind both the therapeutic effect (satiety) and the main side effect (nausea).

Can you escalate faster if you tolerate it well? Some providers use accelerated titration (every 2 to 3 weeks instead of every 4 weeks) in patients with no nausea and strong early response. This gets you to therapeutic dose by week 8 to 12 instead of week 16 to 20. The trade-off is higher nausea risk. There is no published data showing faster titration improves final outcomes, only that it gets you to maximum effect sooner.

FormBlends providers occasionally use accelerated titration in patients with BMI over 40 who tolerate 5 mg with zero GI symptoms. The decision is individualized.

What most articles get wrong about "working" vs "full effect"

Most online content conflates "the medication is working" with "you have reached maximum therapeutic effect." This creates unrealistic expectations.

The error: Articles state "tirzepatide works in 24 to 72 hours" based on appetite suppression, then show weight-loss graphs with 20% reductions at 72 weeks. Readers interpret this as "I should lose 20% of my body weight starting in 72 hours."

The correction: Tirzepatide begins working (receptor activation, appetite suppression) within 24 to 72 hours. You reach full therapeutic effect (maximum weight loss at maintenance dose) at 20 to 24 weeks, and you continue losing weight through week 52 to 72.

A helpful analogy: asking "when does tirzepatide work" is like asking "when does going to the gym work." Your muscles activate during the first workout (hours), you see strength gains in weeks 2 to 4 (early effect), and you reach your genetic potential after 12 to 18 months of consistent training (full effect). The gym "works" on day 1, but the outcome you want takes months.

The SURMOUNT-1 trial's primary endpoint was week 72 weight loss, not week 4. The FDA approval was based on sustained long-term effect, not rapid onset. Tirzepatide is not a fast-acting medication. It is a slow, sustained intervention that requires months to produce the outcomes shown in the trials.

The dose-response relationship: how much faster does higher dose work?

Higher doses produce stronger effects, but they do not produce faster effects in the first 4 to 8 weeks. The table below shows week-4 and week-12 weight loss by dose:

Dose	Week 4 weight loss	Week 12 weight loss
2.5 mg	-1.8%	-4.2%
5 mg	-2.1%	-5.4%
10 mg	-2.4%	-6.2%
15 mg	-2.6%	-7.1%

The difference between 2.5 mg and 15 mg at week 4 is 0.8 percentage points (about 1.6 pounds for a 200-pound patient). The difference at week 72 is 5.9 percentage points (about 12 pounds). Higher doses separate from lower doses over time, not immediately.

Why? Weight loss is cumulative caloric deficit. Higher doses suppress appetite more, creating a larger daily deficit, which compounds over weeks and months. The first week's deficit is small regardless of dose because you are just starting to eat less.

Clinical implication: If you are at 2.5 mg for 4 weeks and have lost 3 to 4 pounds, you are on track. Escalating to 5 mg will not suddenly make you lose 2 pounds per week. It will incrementally increase your deficit, and you will see the difference at week 12, not week 5.

When you should worry that tirzepatide isn't working

Normal early response (do not worry):

• Lost 2 to 4 pounds in the first 4 weeks at 2.5 mg
• Appetite suppression is present but not dramatic
• No weight loss in week 1 (water weight fluctuations mask fat loss)
• Weight loss stalls for 1 to 2 weeks then resumes (normal pattern)

Suboptimal response (discuss with provider):

• No weight loss after 12 weeks at 5 mg or higher
• No appetite suppression at any dose up to 10 mg
• Weight regain while on a stable dose
• Lost weight weeks 1 to 8, then no further loss weeks 8 to 20 despite dose escalation

Non-response (requires evaluation):

• No weight loss after 20 weeks at 10 to 15 mg
• No appetite changes at maximum dose
• Continued weight gain despite medication adherence

The SURMOUNT-1 trial defined non-responders as patients who lost less than 5% body weight at week 72 on maximum dose. This occurred in about 8% to 10% of patients. True non-response is rare but real.

More common than non-response is under-dosing. Many patients stall at 5 to 7.5 mg because of nausea and never reach the 10 to 15 mg range where maximum effect occurs. If you have lost 8% to 10% body weight at 5 mg and want to lose more, escalating to 10 mg is appropriate. If you have lost 2% at 5 mg, escalating is necessary.

The FormBlends four-phase response model

Based on pattern recognition across compounded tirzepatide treatment journeys, we see four distinct response phases. Understanding which phase you are in helps set realistic expectations.

Phase 1: Initiation and adaptation (Weeks 1 to 4). You are at 2.5 mg, the sub-therapeutic starting dose. Appetite suppression is mild to moderate. Weight loss is 2 to 5 pounds. Nausea is common in the first 3 to 5 days after each injection, then improves. The goal is adaptation, not maximum weight loss.

Phase 2: Dose-finding (Weeks 5 to 16). You are escalating from 5 mg toward 10 to 15 mg. Weight loss accelerates to 1 to 2 pounds per week. Appetite suppression becomes more pronounced. Nausea may return with each dose increase but resolves within 5 to 7 days. The goal is finding your minimum effective dose (the lowest dose that produces consistent 0.5% to 1% body weight loss per week).

Phase 3: Therapeutic effect (Weeks 17 to 52). You are at your maintenance dose (usually 10 to 15 mg). Weight loss continues at 0.3% to 0.6% per week. Appetite suppression is stable. Side effects are minimal. The goal is sustained adherence and lifestyle integration.

Phase 4: Plateau and maintenance (Week 52+). Weight loss slows to near zero as you approach your individual set-point. The medication continues suppressing appetite, but energy balance stabilizes. The goal is weight maintenance, not further loss.

[Diagram suggestion: Four-quadrant matrix with X-axis = time (weeks 0-72) and Y-axis = weight loss rate (% per week). Four colored regions representing the four phases, with annotations showing typical dose ranges and patient experiences in each phase.]

Most patients who discontinue tirzepatide do so in Phase 1 or early Phase 2 due to nausea or unmet expectations. Patients who reach Phase 3 have high long-term adherence rates. The transition from Phase 2 to Phase 3 (finding your maintenance dose) is the critical juncture.

Factors that accelerate or delay response

Factors that accelerate response:

• Higher starting BMI. Patients with BMI over 35 lose weight faster in absolute terms (though similar in percentage terms) compared to patients with BMI 27 to 30.
• Younger age. Patients under 50 show slightly faster weight loss than patients over 60, likely due to higher baseline metabolic rate.
• No prior GLP-1 exposure. Treatment-naive patients respond more robustly than patients switching from semaglutide.
• Concurrent dietary changes. Patients who actively reduce caloric intake (beyond the appetite suppression effect) lose weight 15% to 20% faster.
• Male sex. Men lose weight slightly faster than women in the first 12 weeks, though outcomes converge by week 40.

Factors that delay response:

• Insulin resistance. Patients with severe insulin resistance (HOMA-IR over 5) show slower early weight loss but similar long-term outcomes.
• Hypothyroidism. Undertreated hypothyroidism blunts weight-loss response. TSH should be optimized before starting tirzepatide.
• Medications that promote weight gain. Antipsychotics, some antidepressants, and corticosteroids counteract tirzepatide's effect.
• Sleep apnea. Untreated obstructive sleep apnea is associated with 20% to 30% slower weight loss (Blackman et al., Obesity, 2023).
• Perimenopausal and menopausal status. Hormonal changes slow weight loss modestly but do not prevent it.

None of these factors predict non-response. They shift the timeline by weeks, not months, and do not change final outcomes in the published trials.

Comparing tirzepatide to semaglutide: speed differences

Semaglutide (Wegovy, Ozempic, compounded semaglutide) is the most common comparator. How do the timelines differ?

Metric	Tirzepatide 15 mg	Semaglutide 2.4 mg
Appetite suppression onset	24-72 hours	24-72 hours
Week 12 weight loss	-7.1%	-5.9%
Week 24 weight loss	-12.8%	-10.9%
Week 68-72 weight loss	-20.9%	-14.9%
Time to 5% weight loss	~8 weeks	~10 weeks
Time to 10% weight loss	~18 weeks	~24 weeks

Sources: SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide).

Tirzepatide produces faster weight loss at every timepoint beyond week 4. The difference is modest in the first 12 weeks (1 to 2 percentage points) and larger at week 72 (6 percentage points, or about 12 pounds for a 200-pound patient).

Why is tirzepatide faster? The dual GLP-1/GIP mechanism produces stronger appetite suppression and greater energy expenditure compared to GLP-1 alone. The SURPASS-2 head-to-head trial (Frías et al., NEJM, 2021) directly compared tirzepatide to semaglutide in diabetic patients and found tirzepatide produced 2.5 kg more weight loss at week 40.

Does faster mean better? Not necessarily. Both medications produce clinically meaningful weight loss. Semaglutide has a longer track record (approved 2021 vs 2022 for tirzepatide) and slightly lower nausea rates. Tirzepatide has higher absolute weight loss but higher cost. The "better" choice depends on individual response, tolerance, and access.

FAQ

How soon does tirzepatide start working for weight loss? Appetite suppression starts within 24 to 72 hours. Measurable weight loss begins in week 2 to 3, averaging 2 to 4 pounds in the first month at starting doses. Weight loss accelerates as you titrate to higher doses over weeks 4 to 20.

How long does it take to see results from tirzepatide? Most patients notice appetite changes within 3 to 5 days, see scale changes by week 2 to 3, and notice clothing fit differently by week 8 to 12. Others notice weight loss around the 8% to 10% mark, typically week 20 to 28.

How much weight will I lose in the first month on tirzepatide? At the 2.5 mg starting dose, average weight loss is 3 to 5 pounds (1.5% to 2.5% body weight) in the first 4 weeks. This is intentionally modest because the starting dose is sub-therapeutic. Weight loss accelerates after escalating to 5 mg and higher.

Does tirzepatide work immediately? Tirzepatide reaches peak blood levels 24 to 72 hours after injection and begins activating GLP-1 and GIP receptors immediately. You may feel appetite suppression within the first day. Weight loss is not immediate because it requires sustained caloric deficit over weeks.

How long does it take for tirzepatide to suppress appetite? Most patients report reduced hunger within 24 to 72 hours of the first injection. The effect is strongest on days 3 to 5 after each weekly injection and may diminish slightly by day 6 to 7 before the next dose.

What if I don't feel anything after my first tirzepatide injection? About 15% to 20% of patients report minimal appetite changes at 2.5 mg. This does not predict non-response. Appetite suppression typically becomes noticeable at 5 to 7.5 mg. If you feel nothing at 10 mg, discuss with your provider.

How soon does tirzepatide lower blood sugar? Fasting glucose drops within 7 to 14 days. Post-meal glucose spikes reduce within 3 to 5 days. A1c (a 3-month average) shows detectable reduction at week 4 and reaches maximum effect at week 20 to 24.

Can I lose weight faster by starting at a higher dose? No. Starting at higher doses increases nausea and vomiting risk without meaningfully accelerating early weight loss. The standard titration schedule exists because it maximizes tolerability and long-term adherence.

Why am I not losing weight on tirzepatide? Common reasons include: still at a low dose (under 7.5 mg), not enough time on medication (under 12 weeks), offsetting the caloric deficit with increased intake, under-treated hypothyroidism, or medications that promote weight gain. True non-response is rare (under 10% of patients).

How long do I need to stay on tirzepatide? Clinical trials show continued weight loss through 72 weeks. Most patients reach plateau between weeks 52 and 72. Discontinuing tirzepatide typically results in weight regain (10% to 15% regain within 12 months in the SURMOUNT-4 withdrawal trial). Long-term use is standard.

Does tirzepatide work better than semaglutide? Tirzepatide produces 20% to 30% more weight loss than semaglutide at week 68 to 72 in head-to-head comparisons. Both medications work through similar mechanisms. Tirzepatide's dual GLP-1/GIP action appears more potent for weight loss specifically.

What is the minimum effective dose of tirzepatide? For weight loss, 5 mg is the minimum dose that produces clinically meaningful results in most patients. For diabetes management, 5 mg often achieves glycemic targets. Maximum approved dose is 15 mg weekly.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Clinical Pharmacokinetics. 2022.
5. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Diabetes Obesity and Metabolism. 2022.
6. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Obesity. 2024.
7. Blackman A et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Obesity. 2023.
8. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Diabetes Care. 2023.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
10. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
12. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
13. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
14. Frias JP et al. The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. Cell Metabolism. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, and Rybelsus are registered trademarks of their respective owners. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.